New skin test could reveal hidden cancer risks
NCT ID NCT07112287
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new genetic test called the MyeloGen Gene Panel to see if it can quickly and reliably find inherited risks for myeloid cancers (a type of blood cancer). Researchers will take a small skin sample from 200 adults with these cancers and analyze it for genetic changes. The goal is to see if results can be returned within 10 weeks, which could help doctors better understand and manage the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MyeloGen Gene Panel (genetic test using skin fibroblasts)
What this could lead to
If successful, this could make it easier to identify people with inherited risks for myeloid cancers, potentially guiding earlier monitoring or treatment.
What could go wrong
This is an early feasibility study, not a treatment trial. The test may not be faster or more reliable than current methods, and results may not change patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENETIC PREDISPOSITION TO DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact